Human PCSK9 ELISA Kit | PCSK9 elisa kit

PCSK9 (Human) OmniKine ELISA Kit

Cat. Num. AAA9502070

• Gene Names: PCSK9; FH3; PC9; NARC1; LDLCQ1; NARC-1; HCHOLA3
• Reactivity: Human
• Synonyms: PCSK9; PCSK9 (Human) OmniKine ELISA Kit; Proprotein convertase subtilisin/kexin type 9; Neural apoptosis-regulated convertase 1; NARC-1; PC9; Subtilisin/kexin-like protease PC9; NARC1; PSEC0052; PCSK9 elisa kit

• Reactivity: Human
• Specificity: The OmniKine Human Leptin ELISA is capable of recognizing both recombinant and naturally produced Human Leptin proteins. The antigens listed below were tested at 50 ng/ml and exhibited less than 5% cross reactivity.
• Form/Format: 12 x 8-Well Microstrips
• Sequence Length: 692

• Assay Type: Quantitative Sandwich
• Sensitivity: 63-4000 pg/ml.
• Preparation and Storage: Store at 4 degree C for 6 months.

Testing Data

(The OmniKine Human PCSK9 ELISA Kit allows for the detection and quantification of endogenous levels of natural and/or recombinant Human PCSK9 proteins within the range of 125-8000 pg/ml.)

Related Product Information for PCSK9 elisa kit

Principle of the Assay: The OmniKine Human Leptin ELISA Kit contains the components necessary for quantitative determination of natural or recombinant Human Leptin concentrations within any experimental sample including cell lysates, serum and plasma. This particular immunoassay utilizes the quantitative technique of a "Sandwich" Enzyme-Linked Immunosorbent Assay (ELISA) where the target protein (antigen) is bound in a "sandwich" format by the primary capture antibodies coated to each well-bottom and the secondary detection antibodies added subsequently by the investigator. The capture antibodies coated to the bottom of each well are specific for a particular epitope on Human Leptin while the user-added detection antibodies bind to epitopes on the captured target protein. Amid each step of the procedure, a series of wash steps must be performed to ensure the elimination of non-specific binding between proteins to other proteins or to the solid phase. After incubation and "sandwiching" of the target antigen, a peroxidase enzyme is conjugated to the constant heavy chain of the secondary antibody (either covalently or via Avidin/Streptavidin-Biotin interactions), allowing for a colorimetric reaction to ensue upon substrate addition. When the substrate TMB (3, 3', 5, 5'-Tetramethylbenzidine) is added, the reaction catalyzed by peroxidase yields a blue color that is representative of the antigen concentration. Upon sufficient color development, the reaction can be terminated through addition of Stop Solution (2 N Sulfuric Acid) where the color of the solution will turn yellow. The absorbance of each well can then be read by a spectrophotometer, allowing for generation of a standard curve and subsequent determination of protein concentration!!Background/Introduction: Human Leptin, also known as Obesity Factor, is a 167 amino acid cytokine protein encoded by the LEP gene located at locus 7q31.3 on chromosome 7. Leptin may function as part of a signaling pathway that acts to regulate the size of the body fat depot. An increase in the level of LEP may act directly or indirectly on the CNS to inhibit food intake and/or regulate energy expenditure as part of a homeostatic mechanism to maintain constancy of the adipose mass. Defects in LEP may be a cause of obesity, a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the results of excessive accumulation of body fat. Leptin also has several endocrine functions, and is involved in the regulation of immune and inflammatory responses, hematopoiesis, angiogenesis and wound healing. Mutations in the gene and/or its regulatory regions may cause severe obesity and morbid obesity with hypogonadism as well as development of type 2 diabetes mellitus.

NCBI and Uniprot Product Information

• NCBI GI #: 31317307
• NCBI GeneID: 255738
• NCBI Accession #: NP_777596.2
• NCBI GenBank Nucleotide #: NM_174936.3
• UniProt Accession #: Q8NBP7; Q5PSM5; Q5SZQ2; A8T640; C0JYY9
• Molecular Weight: 20,827 Da
• NCBI Official Full Name: proprotein convertase subtilisin/kexin type 9 preproprotein
• NCBI Official Synonym Full Names: proprotein convertase subtilisin/kexin type 9
• NCBI Official Symbol: PCSK9
• NCBI Official Synonym Symbols: FH3; PC9; NARC1; LDLCQ1; NARC-1; HCHOLA3
• NCBI Protein Information: proprotein convertase subtilisin/kexin type 9
• UniProt Protein Name: Proprotein convertase subtilisin/kexin type 9
• Protein Family: Proprotein convertase subtilisin/kexin
• UniProt Gene Name: PCSK9
• UniProt Synonym Gene Names: NARC1; NARC-1; PC9

NCBI Description

This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]

Uniprot Description

PCSK9: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. Defects in PCSK9 are the cause of hypercholesterolemia autosomal dominant type 3 (HCHOLA3). A familial condition characterized by elevated circulating cholesterol contained in either low-density lipoproteins alone or also in very-low-density lipoproteins. Belongs to the peptidase S8 family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Cell development/differentiation; EC 3.4.21.-; Protease; Secreted; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 1p32.3

Cellular Component: cell surface; COPII-coated ER to Golgi transport vesicle; cytoplasm; early endosome; endoplasmic reticulum; endoplasmic reticulum lumen; extracellular region; extracellular space; extrinsic to external side of plasma membrane; Golgi apparatus; late endosome; lysosomal membrane; lysosome; perinuclear region of cytoplasm; plasma membrane; rough endoplasmic reticulum

Molecular Function: apolipoprotein binding; apolipoprotein receptor binding; low-density lipoprotein particle binding; low-density lipoprotein receptor binding; protein binding; protein self-association; receptor inhibitor activity; RNA binding; serine-type endopeptidase activity; sodium channel inhibitor activity; very-low-density lipoprotein binding

Biological Process: apoptosis; cellular protein metabolic process; cellular response to insulin stimulus; cellular response to starvation; cholesterol homeostasis; cholesterol metabolic process; kidney development; lipoprotein metabolic process; liver development; low-density lipoprotein particle receptor catabolic process; lysosomal transport; negative regulation of receptor recycling; neurogenesis; neuron differentiation; phospholipid metabolic process; positive regulation of low-density lipoprotein particle receptor catabolic process; positive regulation of neuron apoptotic process; positive regulation of receptor internalization; post-translational protein modification; protein autoprocessing; regulation of neuron apoptosis; regulation of receptor activity; triacylglycerol metabolic process

Disease: Hypercholesterolemia, Autosomal Dominant, 3